Get the Stockscreener App
0.4903
11.02%
-0.0607
Entero Therapeutics Inc stock is traded at $0.4903, with a volume of 239.08K.
It is down -11.02% in the last 24 hours and up +23.38% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$0.551
Open:
$0.5146
24h Volume:
239.08K
Relative Volume:
0.17
Market Cap:
$2.48M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.71%
1M Performance:
+23.38%
6M Performance:
-16.03%
1Y Performance:
-77.71%
1-Day Range:
$0.4669
$0.53
1-Week Range:
$0.4669
$0.69
52-Week Range:
$0.185
$2.29
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.4903 | 2.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc Stock (ENTO) Latest News
More than 1 million power banks recalled after some consumers report fires - The Globe and Mail
FluroTech Ltd. Announces Change in Directors - TradingView
Thinkific Announces Closing of Secondary Offering of Approximately C$14.5 Million of Rhino Group's Shares - The Globe and Mail
Entero Therapeutics names Richard Paolone interim CEO - MSN
Celiac Disease Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Statistics, Revenue, Prevalence, Medication, Treatment Market and Companies by DelveInsight - The Globe and Mail
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Entero Therapeutics IncNow Offering 15.2 Million Shares Of Common Stock - marketscreener.com
Public market insider buying at Goldshore Resources (GSHR) - The Globe and Mail
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Cattle Strength Pushes Triple Digit Gains at Midday - The Globe and Mail
Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
NuCana Stock Price, Quotes and Forecasts | NASDAQ:NCNA - Benzinga
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Entero Therapeutics, Inc. SEC 10-Q Report - TradingView
Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement - marketscreener.com
Entero Therapeutics Finalizes Settlement with Mattress Liquidators - TipRanks
Entero (ENTO) Announces Public Offering of 16.67 Million Shares - GuruFocus
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Entero Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com South Africa
Entero Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Titan Environmental Solutions Inc. Appoints Edward J. Borkowski and Edward F. Feighan to its Board of Directors - The Manila Times
Strategic Board Shake-Up: Ex-Pharma CFO and Former Congressman Join Titan Environmental's Expansion Push - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
VOO ETF News, 4/1/2025 - The Globe and Mail
Tesla Inc. (TSLA) Stock Analysis & Analyst Coverage Update - The Globe and Mail
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
Celiac Disease Market Expected to Experience Major Growth - openPR
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):